Related Experiment Video
Updated: Feb 7, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
Glucocorticoid-induced CREB activation and myostatin expression in C2C12 myotubes involves phosphodiesterase-3/4
Yang Xie1, Ben D Perry2, Daniel Espinoza3
1Department of Medicine, Renal Division, Emory University, Atlanta, GA 30322, USA; Department of Nephrology, Xiangya Hospital and Xiangya School of Medicine, Central South University, Changsha, Hunan 410008, PR China; Department of Nephrology, Beijing Hospital, Beijing 100730, PR China.
Abstract:
Muscle atrophy in metabolic conditions like chronic kidney disease (CKD) and diabetes are associated with glucocorticoid production, dysfunctional insulin/Akt/FoxO3 signaling and increased myostatin expression. We recently found that CREB, a transcription factor proposed to regulate myostatin expression, is highly phosphorylated in some wasting conditions. Based on a novel Akt-PDE3/4 signaling paradigm, we hypothesized that reduced Akt signaling contributes to CREB activation and myostatin expression. C2C12 myotubes were incubated with dexamethasone (Dex), an atrophy-inducing synthetic glucocorticoid. Akt/CREB signaling and myostatin expression were evaluated by immunoblot and qPCR analyses. Inhibitors of Akt, phosphodiesterase (PDE)-3/4, and protein kinase A (PKA) signaling were used to test our hypothesis. Incubating myotubes with Dex for 3-24 h inhibited Akt phosphorylation and enhanced CREB phosphorylation as well as myostatin mRNA and protein. Inhibition of PI3K/Akt signaling with LY294002 similarly increased CREB phosphorylation. Isobutyl-methylxanthine (IBMX, a pan PDE inhibitor), milrinone (PDE3 inhibitor) and rolipram (PDE4 inhibitor) augmented CREB phosphorylation and myostatin expression. Inhibition of protein kinase A by PKI reverted Dex- or IBMX-induced CREB phosphorylation and myostatin expression. Our study provides evidence supporting a newly identified mechanism by which a glucocorticoid-related reduction in Akt signaling contributes to myostatin expression via CREB activation.
Insights
Glucocorticoids reduce Akt signaling, leading to increased CREB phosphorylation and myostatin expression, contributing to muscle atrophy in metabolic diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- Muscle atrophy in chronic kidney disease (CKD) and diabetes is linked to glucocorticoids, impaired insulin/Akt/FoxO3 signaling, and elevated myostatin.
- CREB (cAMP response element-binding protein) phosphorylation is observed in some wasting conditions and is hypothesized to regulate myostatin.
Purpose of the Study:
- To investigate the hypothesis that reduced Akt signaling contributes to CREB activation and subsequent myostatin expression.
- To elucidate the role of the Akt-PDE3/4 signaling pathway in glucocorticoid-induced muscle atrophy.
Main Methods:
- C2C12 myotubes were treated with dexamethasone (Dex) to induce atrophy.
- Western blotting and qPCR were used to assess Akt/CREB signaling and myostatin expression.
- Inhibitors of Akt, phosphodiesterase (PDE)-3/4, and protein kinase A (PKA) were employed to test the signaling pathway.
Main Results:
- Dexamethasone treatment inhibited Akt phosphorylation while increasing CREB phosphorylation and myostatin expression (mRNA and protein).
- Inhibition of PI3K/Akt signaling mimicked these effects, increasing CREB phosphorylation.
- Inhibitors of PDE3/4 (milrinone, rolipram) and a pan-PDE inhibitor (IBMX) enhanced CREB phosphorylation and myostatin expression.
- PKI, an inhibitor of PKA, reversed the Dex- and IBMX-induced increases in CREB phosphorylation and myostatin expression.
Conclusions:
- Glucocorticoid-induced reduction in Akt signaling activates CREB.
- Activated CREB leads to increased myostatin expression, a mechanism contributing to muscle atrophy in metabolic conditions.
- This study identifies a novel Akt-PDE3/4-PKA-CREB signaling axis involved in glucocorticoid-mediated muscle wasting.
Related Concept Videos
Endocrine Signaling
Intracellular Signaling Cascades
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Bacterial Signaling
What is Cell Signaling?
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

